Analyst Reco. Eli Lilly and Company Lima

Equities

US5324571083

Real-time Estimate Cboe BZX Other stock markets 21:25:08 21/06/2024 BST			5-day change	1st Jan Change
885.5 ^USD	+2.73%		0.00%	0.00%

09:45pm	Weight-loss drug Zepbound resolves sleep apnea in up to 52% of patients, Lilly says	RE
06:22am	Eli Lilly Sues More Wellness Centers, Medical Spas Over Unauthorized Tirzepatide Sales	MT

Analyst Reco.

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

BIOGEN EXEC SAYS THE ALZHEIMER'S DRUG MARKET "WILL DEVELOP FASTE…	06-12	RE
Social Buzz: Wallstreetbets Stocks Mixed Premarket Wednesday; Oracle to Advance, AST SpaceMobile to Open Lower	06-12	MT
Jefferies Adjusts Price Target on Eli Lilly and Co. to $994 From $957	06-11	MT
Jefferies Adjusts Price Target on Eli Lilly to $957 From $925	06-07	MT
Goldman Sachs Adjusts Price Target on Eli Lilly to $785 From $740	05-30	MT
Jefferies Adjusts Price Target on Eli Lilly to $925 From $915	05-23	MT
Social Buzz: Wallstreetbets Stocks Mixed Pre-Bell; Hims & Hers Health to Advance, AMC Entertainment to Decline	05-21	MT
Argus Adjusts Price Target on Eli Lilly to $840 From $770	05-14	MT
Redburn Atlantic Adjusts Eli Lilly Price Target to $600 From $540	05-14	MT
China Merchants Initiates Eli Lilly at Buy Rating With $852 Price Target	05-08	MT
JPMorgan Adjusts Price Target on Eli Lilly to $900 From $850	05-01	MT
Wolfe Research Adjusts Price Target on Eli Lilly to $909 From $813	05-01	MT
Barclays Adjusts Price Target on Eli Lilly and Company to $913 From $810	05-01	MT
BMO Capital Adjusts Eli Lilly Price Target to $1,001 From $900	05-01	MT
Leerink Partners Adjusts Price Target on Eli Lilly to $901 From $821	05-01	MT
Deutsche Bank Adjusts Price Target on Eli Lilly to $725 From $695	05-01	MT
Truist Raises Price Target on Eli Lilly to $892 From $850, Keeps Buy Rating	05-01	MT
Goldman Sachs Adjusts Price Target on Eli Lilly to $740 From $723	05-01	MT
Wells Fargo Adjusts Eli Lilly Price Target to $875 From $825	05-01	MT
Morgan Stanley Raises Price Target on Eli Lilly to $1,023 From $950 Amid 2024 Guidance Boost, Keeps Overweight Rating	05-01	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

David Ricks, CEO of Eli Lilly: A market of over a billion people

March 12, 2024 at 06:47 pm